Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Joseph Stella

Interventional Cardiology Mokena, IL Doctor of Osteopathy

NPI 1104880376 CMS profile 4571

10260 191St St Ste 102, Mokena, IL 60448

Open in the dashboard

General payments

$8,867

571 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Joseph Stella of Mokena, IL is reported in the CMS Open Payments database as having received $8,867 across 571 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 55th percentile of Interventional Cardiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,505 100
2024 General $1,532 97
2023 General $1,313 108
2022 General $905 73
2021 General $820 57
2020 General $690 35
2019 General $1,101 101

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Joseph Stella
  • Interventional Cardiology median
  • Middle half of Interventional Cardiology
  • National median

In program year 2025, general payments to Joseph Stella were reported at $2,505. Among 6,173 Interventional Cardiology profiles paid that year, the median was $1,092 and the middle half received between $366 and $3,019.

Show as a table
Year Joseph Stella Interventional Cardiology median Middle half National median
2019 $1,101 $1,097 $329–$3,048 $163
2020 $690 $473 $161–$1,480 $114
2021 $820 $677 $233–$1,827 $132
2022 $905 $978 $333–$2,724 $149
2023 $1,313 $1,136 $382–$2,986 $160
2024 $1,532 $1,181 $395–$3,326 $164
2025 $2,505 $1,092 $366–$3,019 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Pfizer Inc. $1,376 140 payments
  2. E.R. Squibb & Sons, L.L.C. $1,145 112 payments
  3. Novartis Pharmaceuticals Corporation $1,097 75 payments
  4. AOP Health US, LLC $1,063 3 payments
  5. Janssen Pharmaceuticals, Inc $795 69 payments
  6. ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $536 36 payments
  7. Amgen Inc. $470 28 payments
  8. AstraZeneca Pharmaceuticals LP $269 17 payments
  9. Medtronic, Inc. $250 6 payments
  10. Novo Nordisk Inc $199 8 payments
  11. Other $1,668 77 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $8,776 558 payments
  2. Education $91 13 payments
Products named General payments · program years 2019–2025
  1. ELIQUIS Cardiovascular;Metabolic Disease $1,218 131 payments
  2. Rapiblyk Cardiovascular $1,063 3 payments
  3. Rapiblyk Cardiovascular $1,063 3 payments
  4. XARELTO $795 69 payments
  5. ELIQUIS Cardiovascular $689 74 payments
  6. LifeVest $536 36 payments
  7. LEQVIO $520 37 payments
  8. ENTRESTO $427 31 payments
  9. Repatha $398 24 payments
  10. CAMZYOS $397 32 payments
  11. Other $3,902 250 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 80 drugs

Part D claims

16,433

Median for Interventional Cardiology: 2,236

Drug cost

$2,343,609

Median for Interventional Cardiology: $380,412

Branded share of claims

24.7%

Median for Interventional Cardiology: 27.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 911 $1,191,025
Entresto Sacubitril/Valsartan Brand 312 $498,253
Xarelto Rivaroxaban Brand 180 $255,428
Brilinta Ticagrelor Brand 46 $50,541
Farxiga Dapagliflozin Propanediol Brand 31 $41,569
Repatha Sureclick Evolocumab Brand 43 $41,279
Jardiance Empagliflozin Brand 18 $25,763
Metoprolol Succinate Generic 1,729 $25,682
Atorvastatin Calcium Generic 1,810 $21,344
Valsartan-Hydrochlorothiazide Valsartan/Hydrochlorothiazide Brand 371 $13,532

The 10 drugs with the highest cost, of 80 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 4,694 Part D prescribers listed as Interventional Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 59 billing codes

Paid by Medicare

$653,550

Of which drugs: $1,786

Medicare patients

3,489

Average age 76

Services billed

25,466

1,704 women, 1,785 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 60%
Arthritis 53%
Atrial fibrillation 38%
Diabetes 33%
Heart failure 30%
Chronic kidney disease 29%
COPD 23%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml Q9967 Office 149 15,605 $1,629
Infusion, normal saline solution, 250 cc J7050 Office 44 104 $54

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 14 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
ELIQUIS
  • PFIZER INC. $264
  • E.R. Squibb & Sons, L.L.C. $169
$433 911 —
CAMZYOS
  • E.R. Squibb & Sons, L.L.C. $182
$182 — —
LEQVIO
  • Novartis Pharmaceuticals Corporation $115
$115 — —
ENTRESTO
  • Novartis Pharmaceuticals Corporation $88
$88 312 —
Wegovy
  • Novo Nordisk Inc $75
$75 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 14 in the dashboard with a free account

Records

571 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Cardiology in Illinois

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record